DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its ...

As of November 01, 2024, Sanofi SA (ADR) had a $134.1 billion market capitalization, putting it in the 98th percentile of companies in the Pharmaceuticals industry. Currently, Sanofi SA (ADR)’s ...

A Palo Alto SaaS company has partnered with the Michael J. Fox Foundation for Parkinson’s Research for AI help in identifying ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

Opella Valuation: EUR16 billion EV, 14 times 2024 estimated EBITDA. Sanofi SA (NASDAQ:SNY) reported a strong sales performance with Q3 sales reaching EUR13.4 billion, marking a 16% increase in ...

Opella Valuation: EUR16 billion EV, 14 times 2024 estimated EBITDA. Sanofi SA (NASDAQ:SNY) reported a strong sales performance with Q3 sales reaching EUR13.4 billion, marking a 16% increase in ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...